Antineoplastics
1
Reactions 511 - 23 Jul 1994 Antineoplastics Leukaemia in patients with Hodgkin’s disease: incidence study Patients with Hodgkin’s disease who received chlormethine treatment had the highest risk of developing leukaemia, followed by those patients who received lomustine and teniposide combinations, according to the results of a case- control study conducted in the Netherlands. From a cohort of 1939 patients treated for Hodgkin’s disease over a 20-year period, information from the medical records of 44 patients who developed leukaemia was compared with that from 124 matched controls. Patients who received ≤ 6 cycles of chlormethine and procarbazine had an 8-fold risk of developing leukaemia compared with patients who received radiotherapy alone. Those patients who were given ≥ 6 cycles of this combination antineoplastic therapy had a > 40-fold risk of developing leukaemia. Treatment with lomustine or a combination of teniposide and cyclophosphamide was also associated with a significantly increased risk of leukaemia. Patients who received antineoplastic therapy during 2 or more separate periods had a 40-fold greater risk of leukaemia than those patients who had only 1 episode of antineoplastic therapy. Patients with low platelet counts (< 75 × 10 6 /ml) were found to have a significantly greater risk of leukaemia. Van Leeuwen FE, et al. Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. Journal of Clinical Oncology 12: 1063-1073, May 1994 - Netherlands 800277715 1 Reactions 23 Jul 1994 No. 511 0114-9954/10/0511-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 511 - 23 Jul 1994
Antineoplastics
Leukaemia in patients with Hodgkin’s disease:incidence study
Patients with Hodgkin’s disease who received chlormethinetreatment had the highest risk of developing leukaemia,followed by those patients who received lomustine andteniposide combinations, according to the results of a case-control study conducted in the Netherlands.
From a cohort of 1939 patients treated for Hodgkin’sdisease over a 20-year period, information from the medicalrecords of 44 patients who developed leukaemia wascompared with that from 124 matched controls.
Patients who received ≤ 6 cycles of chlormethine andprocarbazine had an 8-fold risk of developing leukaemiacompared with patients who received radiotherapy alone.Those patients who were given ≥ 6 cycles of this combinationantineoplastic therapy had a > 40-fold risk of developingleukaemia.
Treatment with lomustine or a combination of teniposideand cyclophosphamide was also associated with a significantlyincreased risk of leukaemia. Patients who receivedantineoplastic therapy during 2 or more separate periods had a40-fold greater risk of leukaemia than those patients who hadonly 1 episode of antineoplastic therapy. Patients with lowplatelet counts (< 75 × 106/ml) were found to have asignificantly greater risk of leukaemia.Van Leeuwen FE, et al. Leukemia risk following Hodgkin’s disease: relation tocumulative dose of alkylating agents, treatment with teniposide combinations,number of episodes of chemotherapy, and bone marrow damage. Journal ofClinical Oncology 12: 1063-1073, May 1994 - Netherlands 800277715
1
Reactions 23 Jul 1994 No. 5110114-9954/10/0511-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
